From January 1, 2024 to March 31, 2024, the company has repurchased 11,804,907 shares, representing 1.45% for CNY 222.56 million. With this, the company has completed the repurchase of 17,763,061 shares, representing 2.2% for CNY 345.45 million under the buyback announced on July 17, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
29.3 CNY | -0.10% | +6.39% | +31.80% |
04-26 | Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
04-25 | Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.80% | 3.15B | |
-4.72% | 182B | |
+0.24% | 110B | |
-3.80% | 67.92B | |
+2.68% | 50.96B | |
+9.66% | 44.7B | |
+2.70% | 40.66B | |
+20.73% | 27.6B | |
+4.12% | 26.63B | |
-0.19% | 24.98B |
- Stock Market
- Equities
- 300529 Stock
- News Jafron Biomedical Co.,Ltd.
- Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.